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Abstract The terminal portion of the Janus kinases (Jaks)
contains a divergent FERM (Four-point-one, Ezrin, Radixin,
Moesin) homology domain comprising 19 conserved hydrophobic
regions. To determine the role of this domain in governing
recruitment of Jak1, but not Jak3, to the gp130 subunit of the
interleukin-6 family of cytokine receptors, the interaction of
three Jak1/Jak3 chimeras with gp130 was investigated. Chi-
meras 1, 2 and 3 (Jak1 FERM regions 1^19, 1^18 and 1^8/Jak3,
respectively) were all enzymically active. Chimeras 1 and 2
interacted with the cytoplasmic domain of gp130, although less
efficiently than Jak1. Only chimera 2, however, restored gp130
signalling in Jak1-negative cells. The data are consistent with
recruitment of Jak1 to gp130 through the Jak1 FERM domain,
but also emphasise the likely requirement for precise Jak/
receptor orientation to sustain function. ß 2001 Federation of
European Biochemical Societies. Published by Elsevier Science
B.V. All rights reserved.
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1. Introduction
Janus kinases (Jaks) are a family of cytoplasmic tyrosine
kinases involved in cytokine receptor signalling. There are
four known mammalian Jaks: Jak1, Jak2 and Tyk2, which
are ubiquitously expressed, and Jak3, which is restricted to
cells of haematopoietic origin. Jaks are essential for signalling
in response to numerous cytokines and growth factors. They
are non-covalently associated with cytokine receptors and be-
come activated upon cytokine-induced receptor aggregation.
Activated Jaks phosphorylate tyrosine residues in the cyto-
plasmic tail of the receptors, leading to recruitment and acti-
vation of signal transducers and activators of transcription
(STATs) and other signalling molecules (reviewed in [1]).
The speci¢city of Jak/receptor interactions is likely critical
for cytokine signalling. The Jaks are not equivalent. Di¡erent
Jaks are associated with the various cytokine receptors, and
can play distinct roles in individual receptor complexes. For
example, Jaks 1 and 2 and Tyk2 are all activated in response
to interleukin (IL)-6, but e⁄cient signalling is dependent on
Jak1 [2]. In contrast, Jak2 is the sole Jak activated in response
to erythropoietin (Epo) [3] and triggers the activation of Jak1
in the interferon (IFN)-Q receptor [4]. Clearly, any real under-
standing of cytokine signalling will require adequate de¢nition
of the structure/function relationships of Jak/receptor com-
plexes. The Jaks are known to interact with the cytoplasmic,
membrane proximal, domains of cytokine receptors and, in
the case of the class I receptors including the gp130 subunit
of the IL-6 family receptors, with Box1 and -2 motifs within
these domains [5,6]. Thus, for the cytokine receptors some of
the molecular determinants governing Jak recruitment have
been identi¢ed. Much less, however, is known about the na-
ture of the interacting Jak domain(s), particularly for Jak1.
The Jaks contain seven regions showing high sequence homol-
ogy ^ the Jak homology domains (JH) 1^7 [7]. The most C-
terminal JH region (JH1) is a classical tyrosine kinase domain,
whereas the adjacent JH2 kinase-like domain lacks catalytic
activity, but has been implicated in regulating the kinase ac-
tivity of the JH1 domain [8,9]. Jak deletion and chimera anal-
yses have established the importance of Jak N-termini in in-
teraction with the receptors. In general, for Jak2, Jak3 and
Tyk2, elements within the most N-terminal region encompass-
ing JH6 and JH7 are essential for binding to the receptor, but
substantially larger fragments are required to mediate func-
tional binding [6,10^14]. Accordingly, despite substantial
progress, there is no uniform structural model for Jak/recep-
tor interaction, and the further de¢nition of such interactions
has been hampered until very recently by the lack of structural
information on the N-terminal portion of the Jaks. Sequence
analysis has, however, now identi¢ed, within the N-terminal
region of the Jaks, homology with the band four-point-one,
ezrin, radixin, moesin (FERM) domain (also referred to as
band 4.1/JEF domain, for 4.1, Jak, ERM and FAK) [15].
This domain was ¢rst identi¢ed in the N-termini of these cy-
toskeletal proteins and is involved in targeting them to the
plasma membrane. The FERM domains are approximately
400 amino acids in length and contain 19 conserved hydro-
phobic regions. The X-ray crystal structures of the moesin and
radixin FERM domains were recently solved [16,17] and re-
vealed a clover-shaped structure composed of three compact
subdomains (termed F1, F2, F3 in moesin) that show similar-
ity to ubiquitin (F1), acyl-CoA binding protein (F2) and a
phosphotyrosine binding and pleckstrin homology domains
(F3).
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Here, we were concerned to ask if the predicted Jak1
FERM domain de¢nes a functional unit with respect to Jak/
receptor interaction. To this end, Jak1/Jak3 chimeras were
constructed to determine whether the substitution of the
FERM domain of Jak1 would confer gp130 binding upon
Jak3.
2. Materials and methods
2.1. Cell culture and DNA transfections
Jak1-negative mutant U4C cells were derived from HT1080 ¢bro-
sarcoma cells, which do not express Jak3, as described previously
[12,18]. Cells were cultured in Dulbecco’s modi¢ed Eagle’s medium
supplemented with 10% heat-inactivated foetal calf serum and 400
Wg/ml neomycin (G418, Gibco BRL). Transfections of the various
expression constructs (10 Wg total DNA per 10 cm culture dish)
were carried out using Superfect (Qiagen), according to manufactur-
er’s instructions.
2.2. Plasmids and generation of Jak1/Jak3 chimeras
The expression constructs for Jak1 [19], Jak3 [20], Jak1.KE [4], IL-
5RL/gp130 [21] and erythropoietin receptor (EpoR)/gp130 [22] have
been described previously. The Jak1/Jak3 chimeras were generated by
fusion PCR [23] with the junctions at the following amino acid posi-
tions: Jak1 415/Jak3 363 (chimera 1), Jak1 404/Jak3 353 (chimera 2),
Jak1 183/Jak3 169 (chimera 3). All chimeric constructs were subcloned
into the pcDNA 3.1 expression vector (Invitrogen) and were checked
by automated DNA cycle sequencing.
2.3. Cell lysis, (co-) immunoprecipitation and Western blotting
Immuno- and co-immunoprecipitations were performed 24 h after
transfection. For immunoprecipitations and electrophoresis mobility
shift assay (EMSA; see below), cells were lysed in 0.5% NP40, 50 mM
Tris (pH 8.0), 10% glycerol, 150 mM NaCl, 1 mM dithiothreitol,
1 mM EDTA, 1 mM sodium orthovanadate, 1 mM phenylmethylsul-
fonyl £uoride (PMSF), 100 U/ml aprotinin, and 1 Wg/ml leupeptin.
For co-immunoprecipitations, cells were lysed in 1% Brij 97, 20 mM
Tris (pH 8.0), 150 mM NaCl, 1 mM EDTA, 10 mM NaF, 1 mM
sodium orthovanadate, 1 mM PMSF, 100 U/ml aprotinin, and 1 Wg/ml
leupeptin. Lysates were cleared by centrifugation and were subse-
quently incubated with appropriate antibodies (16^18 h at 4‡C) and
protein A^Sepharose (1 h at 4‡C), washed three times in lysis bu¡er
C
Fig. 1. Expression and catalytic activity of Jak1/Jak3 chimeras.
A: Schematic diagram of the Jak1/Jak3 chimeras. JH domains 7^1
are indicated (top). Junctions between Jak1 and 3 are indicated by
the arrowheads; numbers to the left and right of the arrowheads
represent the amino acid positions in Jak1 and 3, respectively.
B: Alignment of the C-terminal amino acid sequences of the FERM
domains of Jak1 (P23458) Jak3 (P52333) and moesin (P26038). The
Jak1/Jak3 junctions of chimeras 1 and 2 are indicated. The positions
of the K-helix and initial residues of the linker are based on the
X-ray crystal structure of the moesin FERM domain [16]. The as-
terisk indicates the last residue of the crystalised moesin FERM do-
main fragment. C: U4C cells which lack both Jak1 and Jak3 were
transiently transfected with the indicated expression plasmids. After
24 h, whole cell lysates were prepared and immunoprecipitated with
either anti-Jak1 (J1) or anti-Jak3 (J3) antibodies as indicated (IP).
The Jak3 antibody was raised against the C-terminus of Jak3 and
was suitable for both immunoprecipitation and detection of the
Jak1/Jak3 chimeras. Blots were probed with anti-phosphotyrosine
antibodies (K-P-Tyr; top panel), and examined for Jak1.KE and
Jak1 protein (middle panel) and Jak3 and chimera protein (bottom
panel) by reprobing blots with Jak1 or Jak3 antibodies as indicated.
D: U4C cells were co-transfected with the kinase-dead Jak1.KE mu-
tant and empty vector (pcDNA 3.1) or expression plasmids encod-
ing wild-type Jak3 or Jak1/Jak3 chimeras. After 24 h, whole cell ly-
sates were prepared and immunoprecipitated with anti-Jak1 (J1).
Blots were probed with phosphotyrosine antibodies (K-P-Tyr; upper
panel) and examined for Jak1.KE protein (lower panel). Arrows in-
dicate the various Jaks and chimeras. Results are representative of
four independent experiments.
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and electrophoresed on 6.5% polyacrylamide^SDS gels. Proteins were
transferred to polyvinylidene £uoride membranes (Immobilon-P,
Millipore), and Western blot analyses were performed as described
previously [24]. The following antibodies were used: polyclonal anti-
bodies against Jak1 (HR 785), Jak3 (C21) and IL-5RL (N20)(all from
Santa Cruz Biotech.), and monoclonal anti-phosphotyrosine antibod-
ies PY20 (A⁄niti) and 4G10 (Upstate Biotechnology). Following en-
hanced chemoluminescence and autoradiography, membranes were
stripped in 62.5 mM Tris (pH 6.8), 2% SDS and 100 mM L-mercap-
toethanol, and then reprobed as required.
2.4. EMSA
24 h after transfection, cells were stimulated for 20 min with Epo
(100 U/ml; a generous gift from Dr B. Hilger, Roche Diagnostics
GmbH), and lysed as described above. EMSAs were performed, as
described previously [12], using a double-stranded 32P-end-labelled
oligonucleotide containing the mutated SIE site from the c-fos pro-
moter (5’-GTCGACATTTCCCGTAAATC-3’) [25].
3. Results
Three Jak1/Jak3 chimeras were constructed (Fig. 1A). Chi-
mera 1 contains the entire Jak1 FERM domain, including all
19 conserved hydrophobic regions. For chimeras 2 and 3, the
junctions between Jak1 and Jak3 were made within the
stretches of highly conserved residues in FERM regions 18
and 8, respectively. C-terminal sequences of the Jak1 and
Jak3 FERM domains, including the Jak1/Jak3 junctions of
chimeras 1 and 2, are shown in Fig. 1B. The rational for
chimera 3 re£ects the original suggestion that the FERM do-
main consists of two duplicated modules, the more N-terminal
of which encompasses FERM regions 1^8 [26]. The more
recently available crystal structures indicate, however, that
the FERM domain is composed of three structural subdo-
mains with no evidence for a duplication [16,17]. Accordingly,
here, chimera 3 serves mainly as a negative control.
3.1. Expression and catalytic activity of Jak1/Jak3 chimeras
The Jak1/Jak3 chimeras, wild-type Jak1 and 3 and a kinase-
negative Jak1, Jak1.KE, were independently expressed in U4C
cells which lack both Jak1 and Jak3 (Section 2). Western blot
analyses of Jak protein (Fig. 1C, lower panels) and Jak tyro-
sine phosphorylation (Fig. 1C, upper panel) indicated that
Jaks 1 and 3 and the chimeras were comparably expressed
and similarly enzymically active. Transiently expressed Jaks
constitutively autophosphorylate [27]. Consistent with this,
the transfected Jaks 1 and 3 and all three chimeras were com-
parably phosphorylated (Fig. 1C, upper panel). The Jak1.KE
was, however, phosphorylated only when co-transfected with
Jak3 or the chimeras (Fig. 1D). Furthermore, all three chime-
ras induced weak constitutive STAT5 DNA-binding activity
(data not shown). Thus, all three chimeras were similarly ex-
pressed and have full auto- and ‘trans’-kinase activity.
3.2. Binding of Jak1/Jak3 chimeras to the cytoplasmic domain
of gp130
To assess the ability of the Jak1/Jak3 chimeras to interact
constitutively with gp130, co-immunoprecipitation experi-
ments were performed. The chimeric receptor IL-5RL/gp130,
comprising the extracellular part of IL-5RL and the trans-
membrane and intracellular tail of gp130 (successfully em-
ployed previously in this type of experiment [28]), was used
again here. U4C cells were transiently co-transfected with this
receptor and the various Jaks and chimeras. The latter were
immunoprecipitated with appropriate Jak antibodies, and co-
precipitation of IL-5RL/gp130 was examined by probing the
blots with an appropriate antibody to IL-5RL. As expected,
the IL-5RL/gp130 receptor co-precipitated with Jak1 but not
Jak3 (Fig. 2, upper panel, lanes 3 and 4). Chimera 1, which
contains the entire Jak1 FERM domain, interacted with the
intracellular gp130 domain, comparably to Jak1 (Fig. 2, lane
5). Chimera 2, in which the last 11 C-terminal amino acids of
the Jak1 FERM domain were replaced with the corresponding
Jak3 amino acids (Fig. 1B), also interacted, but with much
less e⁄ciently (Fig. 2, lane 6). No binding was observed for
chimera 3 (Fig. 2, lane 7). Expression from the various con-
structs was similar as assessed by Western blot analyses of
whole cell lysates (Fig. 2, lower panels). It would appear,
therefore, that a region corresponding to the FERM domain
of Jak1 can confer e⁄cient binding to the cytoplasmic domain
of gp130 upon Jak3.
3.3. Jak1/Jak3 chimera 2 sustains gp130-mediated signalling in
Jak1-negative cells
Next, we determined whether the Jak1/Jak3 chimeras could
restore Jak1-dependent signalling in response to ligand in
Jak1-negative cells. For a ligand-mediated response, the IL-
5RL/gp130 receptor requires co-expression of the complemen-
tary IL-5 receptor subunit, IL-5RK/gp130 [21]. Accordingly
for simplicity, here, use of the homodimeric erythropoietin/
gp130 receptor chimera (EpoR/gp130: EpoR external do-
main/gp130 transmembrane and internal domain [22]) was
preferred. As expected, in Jak1-negative U4C cells co-trans-
fection of Jak1 with the EpoR/gp130 chimera restored Epo-
mediated activation of STAT1 (Fig. 3, lanes 2 and 4, and [2]).
Fig. 2. Binding of Jak1/Jak3 chimeras to the cytoplasmic domain of
gp130. U4C cells were transiently co-transfected with the chimeric
receptor construct IL-5RL/gp130 (encoding the ectodomain of
IL-5RL and the transmembrane and intracellular regions of gp130)
and either empty vector (pcDNA 3.1) or Jak1, Jak3, or chimera 1,
2 or 3. After 24 h, whole cell lysates were prepared and immunopre-
cipitated with either anti-Jak1 (J1) or anti-Jak3 (J3) as indicated
(IP). Blots were probed with antibodies directed against the ectodo-
main of IL-5RL (upper panel). In parallel, samples of the whole cell
lysates were electrophoresed, blotted, and examined for protein ex-
pression (lower panels). Arrows indicate the chimeric receptor IL-
5RL/gp130 and the Jaks and Jak1/Jak3 chimeras. Results are repre-
sentative of four independent experiments.
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Consistent with the co-precipitation data (Fig. 2), neither Jak3
nor chimera 3 rescued STAT1 activation (Fig. 3, lanes 6 and
12). Despite good binding to the IL-5RL/gp130 (Fig. 2), chi-
mera 1 could not substitute for Jak1 with respect to signalling
through the EpoR/gp130 chimera (Fig. 3, lane 8). More pos-
itively, chimera 2, which also bound the IL-5RL/gp130 recep-
tor subunit, although less e⁄ciently (Fig. 2), did restore
STAT1 activation (Fig. 3, lane 10). Thus, it would appear
that ligation of Jak1/Jak3 within the highly conserved
FERM region 18, although detrimental to receptor binding,
has better conserved functionality in chimera 2.
4. Discussion
All three Jak1/Jak3 chimeras were similarly expressed and
retained both auto- and trans-kinase activities comparable to
that of the parental Jaks 1 and 3 (Fig. 1).
Chimera 2, for which the Jak1 substitution of the Jak3
FERM domain includes all but the last 11 C-terminal amino
acids, both bound the cytoplasmic gp130 domain of the IL-
5RL/gp130 receptor subunit and restored ligand-dependent
signalling to STAT1 through the EpoR/gp130 receptor
(Figs. 2 and 3). Although the binding and signalling were
reduced compared to those observed with Jak1, they were
clear and reproducible. It is reasonable to conclude that the
region of Jak1 encompassing the FERM domain is su⁄cient
to mediate functional binding to the cytoplasmic domain of
gp130. Very weak activation of STAT1 was also observed in
response to IFN-Q through the endogenous class II IFN-Q
receptor (data not presented). Accordingly, receptor recruit-
ment of the Jak1/Jak3 chimeras is not an artefact of over-
expression of the chimeric receptors in the transient co-trans-
fection assays. In addition, it suggests that the FERM domain
likely plays a role in the recruitment of Jak1 not only to class
I, but also to class II cytokine receptors.
Chimera 1, in which there is substitution of the entire Jak1
for Jak3 FERM domain, bound the IL-5RL/gp130 chimera
comparably to Jak1 (Fig. 2), but did not signal through the
EpoR/gp130 receptor (Fig. 3). In the absence of appropriate
antibody, the possibility that this re£ects a failure to bind to
the latter cannot be excluded, but seems intrinsically unlikely.
In fact, there are numerous other examples where binding of a
Jak deletion mutant or chimera has not conferred function.
For example, a Jak3/Jak1 chimera having all of JH7 and ¢ve
amino acids of JH6 of Jak3 interacted with the Qc receptor
subunit, but did not signal, whereas a chimera with the more
substantial substitution of both JH6 and JH7 domains was
functional [14]. Similar results have been reported for Tyk2
[13]. More importantly, relative to the discrepancy observed
here between the two very closely related chimeras 1 and 2, a
recent study of Jak2 has emphasised the requirement for very
precise orientation of the Jak kinase domains in the EpoR
complex for function as distinct from binding [29]. In this
respect, it is of interest to note that based on the X-ray crystal
structure of the human moesin FERM domain [16], the Jak1/
Jak3 junction in chimera 1 is in the linker region that connects
the Jak FERM domain to the putative SH2-like domain (Fig.
1B) [15]. Although this junction does not appear to interfere
with the functions of the Jak1 FERM- and Jak3 kinase-do-
mains per se, it may be that it alters the positioning of the
kinase domain in the receptor complex, impairing the phos-
phorylation of receptor-associated substrates.
It is also possible, if not likely, that there is di¡erential
Jak1/Jak3 substrate speci¢city for STAT1 and/or gp130.
Clearly, any such di¡erentiation cannot be absolute as signi¢-
cant activation of STAT1 was observed with chimera 2, de-
spite relatively poor binding to the receptor. On the other
hand, low ligand-independent activation of STAT1 was ob-
served upon overexpression of Jak1, but not the chimeras
(Fig. 3, compare lane 3 with lanes 7, 9 and 11). Thus, some
degree of substrate speci¢city may contribute to the limited
restoration of function observed.
A recent mutational analysis of the N-terminal portion of
Jak1 has identi¢ed, in the FERM F1 subdomain, amino acids
crucial for the interaction with gp130 and the IFN-Q receptor
(C. Haan, H. Is’harc, H. Hermanns, H. Schmitz-Van de Leur,
I. Kerr, P. Heinrich, J. Groetzinger, I. Behrmann, submitted).
Here, a complementary approach has shown that a region
encompassing the Jak1 FERM domain can confer upon
Jak3 the ability to bind gp130. These data, together with
predictions from the recent crystal structures for the FERM
domains of moesin and radixin [16,17], provide a substantial
base upon which to build the further analysis of Jak1/recep-
tor/signalling protein interactions, leading ultimately to the
full de¢nition of functional Jak/receptor complexes.
Acknowledgements: We thank Neil McDonald for helpful discussions
and for comments on the manuscript. C.M.U.H. was supported by a
fellowship from the European Molecular Biology Organisation
(EMBO).
References
[1] Stark, G.R., Kerr, I.M., Williams, B.R.G., Silverman, R.H. and
Schreiber, R.D. (1998) Annu. Rev. Biochem. 67, 227^264.
[2] Guschin, D., Rogers, N., Briscoe, J., Witthuhn, B., Watling, D.,
Horn, F., Pellegrini, S., Yasukawa, K., Heinrich, P., Stark, G.R.,
Ihle, J.N. and Kerr, I.M. (1995) EMBO J. 14, 1421^1429.
[3] Witthuhn, B.A., Quelle, F.W., Silvennoinen, O., Yi, T., Tang, B.,
Miura, O. and Ihle, J.N. (1993) Cell 74, 227^236.
[4] Briscoe, J., Rogers, N.C., Witthuhn, B.A., Watling, D., Harpur,
A.G., Wilks, A.F., Stark, G.R., Ihle, J.N. and Kerr, I.M. (1996)
EMBO J. 15, 799^809.
[5] Murakami, M., Narazaki, M., Hibi, M., Yawata, H., Yasukawa,
K., Hamaguchi, M., Taga, T. and Kishimoto, T. (1991) Proc.
Natl. Acad. Sci. USA 88, 11349^11353.
[6] Tanner, J.W., Chen, W., Young, R.L. and Longmore, G.D.
(1995) J. Biol. Chem. 270, 6523^6530.
Fig. 3. Jak1/Jak3 chimera 2 sustains gp130-mediated signalling in
Jak1-negative cells. U4C cells were co-transfected with the chimeric
receptor construct EpoR/gp130 (encoding the ectodomain of EpoR
and the transmembrane and intracellular regions of gp130) and ei-
ther empty vector (pcDNA 3.1) or Jak3 or chimera 1, 2 or 3. After
24 h, cells were treated with Epo for 20 min where indicated, and
whole cell extracts were prepared and analysed for STAT1 homo-
dimers (arrow) by EMSA using the SIE probe. Results are represen-
tative of four independent experiments.
FEBS 25189 4-9-01
C.M.U. Hilkens et al./FEBS Letters 505 (2001) 87^9190
[7] Harpur, A.G., Andres, A.-C., Ziemiecki, A., Aston, R.R. and
Wilks, A.F. (1992) Oncogene 7, 1347^1353.
[8] Yeh, T.C., Dondi, E., Uze, G. and Pellegrini, S. (2000) Proc.
Natl. Acad. Sci. USA 97, 8991^8996.
[9] Saharinen, P., Takaluoma, K. and Silvennoinen, O. (2000) Mol.
Cell. Biol. 20, 3387^3395.
[10] Zhao, Y., Wagner, F., Frank, S.J. and Kraft, A.S. (1995) J. Biol.
Chem. 270, 13814^13818.
[11] Frank, S.J., Yi, W., Zhao, Y., Goldsmith, J.F., Gilliland, G.,
Jiang, J., Sakai, I. and Kraft, A.S. (1995) J. Biol. Chem. 270,
14776^14785.
[12] Kohlhuber, F., Rogers, N.C., Watling, D., Feng, J., Guscin, D.,
Briscoe, J., Withuhn, B.A., Kotenko, S.V., Pestka, S., Stark,
G.R., Ihle, J. and Kerr, I.M. (1997) Mol. Cell. Biol. 17, 695^
706.
[13] Richter, M.F., Dumenil, G., Uze, G., Fellous, M. and Pellegrini,
S. (1998) J. Biol. Chem. 273, 24723^24729.
[14] Cacalano, N.A., Migone, T.-S., Bazan, F., Hanson, E.P., Chen,
M., Candotti, F., O’Shea, J.J. and Johnston, J.A. (1999) EMBO
J. 18, 1549^1558.
[15] Girault, J.-A., Labesse, G., Mornon, J.-P. and Callebaut, I.
(1999) Trends Biochem. Sci. 24, 54^57.
[16] Pearson, M.A., Reczek, D., Bretscher, A. and Karplus, P.A.
(2000) Cell 101, 259^270.
[17] Hamada, K., Shimizu, T., Matsui, T., Tsukita, S. and Hakoshi-
ma, T. (2000) EMBO J. 19, 4449^4462.
[18] Watling, D., Guschin, D., Muller, M., Silvennoinen, O., Wit-
thuhn, B.A., Quelle, F.W., Rogers, N.C., Schindler, C., Stark,
G.R., Ihle, J.N. and Kerr, I.M. (1993) Nature 366, 166^170.
[19] Wilks, A.F., Harpur, A.G., Kurban, R.R., Ralph, S.J., Zurcher,
G. and Ziemiecki, A. (1991) Mol. Cell. Biol. 11, 2057^2065.
[20] Russell, S.M., Johnston, J.A., Noguchi, M., Kawamura, M., Ba-
con, C.M., Friedmann, M., Berg, M., McVicar, D.W., Witthuhn,
B.A., Silvennoinen, O., Goldman, A.S., Schmalsteig, F.C., Ihle,
J.N., O’Shea, J.J. and Leonard, W.J. (1994) Science 266, 1042^
1045.
[21] Behrmann, I., Janzen, C., Gerhartz, C., Schmitz-Van de Leur,
H., Hermanns, H., Heesel, B., Graeve, L., Horn, F., Tavernier, J.
and Heinrich, P.C. (1997) J. Biol. Chem. 272, 5269^5274.
[22] Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkati, G.,
Grotzinger, J., Wollmer, A., Zhong, Z., Darnell Jr., J.E., Graeve,
L., Heinrich, P.C. and Horn, F. (1996) J. Biol. Chem. 271,
12999^13007.
[23] Clackson, T. and Winter, G. (1989) Nucleic Acids Res. 17,
10163^10170.
[24] Burfoot, M.S., Rogers, N.C., Watling, D., Smith, J.M., Pons, S.,
Paonessaw, G., Pellegrini, S., White, M.F. and Kerr, I.M. (1997)
J. Biol. Chem. 272, 24183^24190.
[25] Wagner, B.J., Hayes, T.E., Hoban, C.J. and Cochran, B.H.
(1990) EMBO J. 9, 4477^4484.
[26] Girault, J.-A., Labesse, G., Mornon, J.-P. and Callebaut, I.
(1998) Mol. Med. 4, 751^769.
[27] Silvennoinen, O., Ihle, J.N., Schlessinger, J. and Levy, D.E.
(1993) Nature 366, 583^585.
[28] Haan, C., Hermanns, H.M., Heinrich, P.C. and Behrmann, I.
(2000) Biochem. J. 349, 261^266.
[29] Constantinescu, S.N., Huang, L.J., Nam, H. and Lodish, H.F.
(2001) Mol. Cell 7, 377^385.
FEBS 25189 4-9-01
C.M.U. Hilkens et al./FEBS Letters 505 (2001) 87^91 91
